Both experimental and clinical studies suggest that inhibin plays a critical role in the development of granulosa cell tumors (GCT), a subgroup of malignant ovarian tumors. Inhibin has been proposed as a biological marker for the followup of patients bearing these particular tumors. Hitherto, there is no general agreement on the molecular form(s) of the inhibin family that are secreted by malignant granulosa cells. Using specific and sensitive immunoassays for activin A and for inhibins A and B, we investigated the production of these molecules in patients with either an adult GCT (n=13) or an epithelial ovarian cancer (n=11). Results showed that serum activin A level was increased in all patients, independently of their clinical status (progressive disease or remission) in comparison to that observed in the healthy pre-and postmenopausal women. Most of the patients also presented a moderate increase in serum inhibin A level compared to that in controls. Only one of eight patients with a progressive granulosa cell tumor had a high value of serum inhibin A. In contrast, serum inhibin B was dramatically increased in eight of nine patients with a granulosa cell tumor and its level correlated with the clinical status of the patients. No correlation was found between the level of serum inhibin B and that of serum antimullerian hormone, a recently described specific and reliable marker for GCT. None of the patients with an epithelial ovarian cancer presented an increase of serum inhibin B. These observations demonstrate that inhibin B; is the major molecular form of the inhibin family proteins produced by malignant granulosa cells.

Petraglia, F., Luisi, S., Pautier, P., Sabourin, J.C., Rey, R., Lhomme, C., et al. (1998). Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 83(3), 1029-1032 [10.1210/jc.83.3.1029].

Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors

PETRAGLIA, F.;LUISI, S.;
1998-01-01

Abstract

Both experimental and clinical studies suggest that inhibin plays a critical role in the development of granulosa cell tumors (GCT), a subgroup of malignant ovarian tumors. Inhibin has been proposed as a biological marker for the followup of patients bearing these particular tumors. Hitherto, there is no general agreement on the molecular form(s) of the inhibin family that are secreted by malignant granulosa cells. Using specific and sensitive immunoassays for activin A and for inhibins A and B, we investigated the production of these molecules in patients with either an adult GCT (n=13) or an epithelial ovarian cancer (n=11). Results showed that serum activin A level was increased in all patients, independently of their clinical status (progressive disease or remission) in comparison to that observed in the healthy pre-and postmenopausal women. Most of the patients also presented a moderate increase in serum inhibin A level compared to that in controls. Only one of eight patients with a progressive granulosa cell tumor had a high value of serum inhibin A. In contrast, serum inhibin B was dramatically increased in eight of nine patients with a granulosa cell tumor and its level correlated with the clinical status of the patients. No correlation was found between the level of serum inhibin B and that of serum antimullerian hormone, a recently described specific and reliable marker for GCT. None of the patients with an epithelial ovarian cancer presented an increase of serum inhibin B. These observations demonstrate that inhibin B; is the major molecular form of the inhibin family proteins produced by malignant granulosa cells.
1998
Petraglia, F., Luisi, S., Pautier, P., Sabourin, J.C., Rey, R., Lhomme, C., et al. (1998). Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 83(3), 1029-1032 [10.1210/jc.83.3.1029].
File in questo prodotto:
File Dimensione Formato  
jcem1029.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 749.39 kB
Formato Adobe PDF
749.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/3232
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo